VIA
AXSM icon

Virtus Investment Advisers’s Axsome Therapeutics AXSM Stock Holding History

Virtus Investment Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Sell
4,557
-1,141
-20% -$247K 0.26% 186
2026
Q1 		$963K Buy
5,698
+1,087
+24% +$188K 0.27% 144
2025
Q4 		$842K Buy
4,611
+428
+10% +$59.8K 0.23% 139
2025
Q3 		$508K Hold
4,183
– – 0.15% 205
2025
Q2 		$437K Buy
4,183
+377
+10% +$39.9K 0.15% 208
2025
Q1 		$444K Buy
+3,806
New +$434K 0.12% 203

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtus Investment Advisers's AXSM Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Axsome Therapeutics (AXSM) stake by 20% in Q2 2026, selling an estimated $247K and leaving 4,557 shares worth $1.12M. The position accounts for 0.26% of the portfolio, ranked #186.

Virtus Investment Advisers first reported a position in AXSM in Q1 2025 and has held it in 6 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Virtus Investment Advisers held 4,557 shares of Axsome Therapeutics worth $1.12M as of Q2 2026.
  • Virtus Investment Advisers sold 1,141 Axsome Therapeutics shares in Q2 2026, an estimated $247K.
  • Axsome Therapeutics made up 0.26% of Virtus Investment Advisers's portfolio in Q2 2026, its #186 holding.
  • Virtus Investment Advisers first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.